Direct Challenges for the Evaluation of Beta-Lactam Allergy: Evidence and Conditions for Not Performing Skin Testing.
Melissa Iammatteo, Guillaume Lezmi, Ronit Confino-Cohen...
https://pubmed.ncbi.nlm.nih.gov/34366093/Actively Recruiting
Led by James Tarbox, MD · Updated on 2025-05-01
380
Participants Needed
1
Research Sites
21 weeks
Total Duration
This research aims to understand dosing in adults labeled as penicillin-allergic but considered low risk for allergic reactions. It compares whether a single-dose oral challenge with amoxicillin is as safe and effective as the traditional two-dose graded oral challenge. The study focuses on removing inaccurate penicillin allergy labels to reduce unnecessary avoidance of penicillin antibiotics. Participants will be randomly assigned to one of two groups one receiving a single placebo dose followed by a full dose of amoxicillin, and the other receiving a two-step graded dose of amoxicillin given 30 minutes apart. Both groups receive the same total amoxicillin dose and are observed closely for allergic reactions during and after the challenge. Follow-up contacts occur 5 days and 6 months later to monitor for any delayed or subsequent reactions. During the study, vital signs are monitored before and after dosing, and any reactions are treated appropriately. The main measure is the proportion of participants successfully delabeled five days after the challenge. Researchers will also analyze adverse reactions, medical history, demographics, and long-term delabeling validation. Total participation includes outpatient dosing and follow-up phone calls up to six months post-challenge.
CONDITIONS
Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge
S
Study Coordinator
J
Joshua A Peterson, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
James Tarbox, MD
Lead Sponsor
Texas Tech University Health Sciences Center
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | One‑dose amoxicillin challenge | Graded two‑dose amoxicillin challenge | No direct oral challenge (usual practice) |
|---|---|---|---|
| What it is | A randomized arm where participants receive a single 250 mg oral dose of amoxicillin (after placebo) to assess penicillin allergy delabeling. | A randomized arm where participants get a graded two‑dose oral amoxicillin challenge (62.5 mg followed by 187.5 mg) to assess delabeling. | The usual approach is to evaluate allergy based on history without performing a direct oral challenge. |
| Role in the trial | Investigational method being randomized for safety and delabeling effectiveness. | Active comparator arm using a graded dosing protocol to evaluate delabeling. | Represents clinical care option outside of the research setting without direct challenge. |
| Purpose | To test if a single‑dose challenge safely allows delabeling of penicillin allergy. | To test if graded two‑dose challenge safely allows delabeling of penicillin allergy. | To guide clinical decision making by maintaining the penicillin allergy label without challenge. |
| How it is done | Participants receive placebo then one 250 mg oral amoxicillin dose. | Participants receive 62.5 mg oral amoxicillin followed by 187.5 mg in a graded challenge. | Clinical evaluation relies on medical history without administering amoxicillin. |
| Evidence status | Efficacy for delabeling via single‑dose oral challenge is under evaluation in this trial; existing evidence includes similar low‑risk challenges. | Efficacy for delabeling via graded two‑dose challenge is under evaluation in this trial; existing evidence for graded protocols is limited. | Relying on history alone may miss opportunities to safely delabel low‑risk allergies, according to recent guidelines. |
| Important risks | Possible allergic reaction during challenge including mild to moderate symptoms. | Possible allergic reaction during graded dosing, potentially milder initial dose but risk during second dose remains. | Avoiding challenge avoids immediate reaction risk but perpetuates allergy label, which may impact future antibiotic use. |
| Important limitations | Findings apply only to low‑risk penicillin allergy; may not apply to higher‑risk individuals. | Graded two‑dose method may require more time and staffing; applicability outside controlled setting may vary. | History‑only evaluation cannot confirm or remove incorrect allergy labels, limiting antibiotic options. |
| Patient impact | Successful delabeling may expand safe antibiotic options for participants. | Successful delabeling via graded approach may similarly broaden antibiotic options, though evidence is less clear. | Continuing the allergy label can limit antibiotic choices, potentially leading to broader‑spectrum use. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 hours on treatment day
Participants receive either a one-dose or a two-dose graded direct oral challenge with amoxicillin to test for penicillin allergy delabeling. They are observed closely for reactions during and immediately after dosing.
1 visit (in-person) on treatment day with monitoring before, during, and after dosing
Duration - 6 months
Participants are contacted by phone approximately 5 days after the treatment to check for any delayed reactions and again at 6 months to assess for any reactions after delabeling.
2 phone calls (at 5 days and 6 months post-treatment)
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Melissa Iammatteo, Guillaume Lezmi, Ronit Confino-Cohen...
https://pubmed.ncbi.nlm.nih.gov/34366093/Jason A Trubiano, Olivia Smibert, Abby Douglas...
https://pubmed.ncbi.nlm.nih.gov/30547046/Merin Kuruvilla, Jennifer Shih, Kiran Patel...
https://pubmed.ncbi.nlm.nih.gov/30582497/Silabhakta Livirya, Alan Pithie, Ignatius Chua...
https://pubmed.ncbi.nlm.nih.gov/32672891/L Lin, J E Nagtegaal, P C A M Buijtels...
https://pubmed.ncbi.nlm.nih.gov/31618608/Melissa Iammatteo, Santiago Alvarez Arango, Denisa Ferastraoaru...
https://pubmed.ncbi.nlm.nih.gov/29802906/Jason A Trubiano, Sara Vogrin, Kyra Y L Chua...
https://pubmed.ncbi.nlm.nih.gov/32176248/Ana Maria Copaescu, Sara Vogrin, Fiona James...
https://pubmed.ncbi.nlm.nih.gov/37459086/Kyra Y L Chua, Sara Vogrin, Susan Bury...
https://pubmed.ncbi.nlm.nih.gov/32756983/Mark H Tucker, Chad M Lomas, Nanda Ramchandar...
https://pubmed.ncbi.nlm.nih.gov/28341170/James Tarbox, MD
Lead Sponsor
Texas Tech University Health Sciences Center
Collaborating Sponsor